The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [ 177 Lu]Lu-DOTATATE.
Marco MaccauroMariarosaria CuomoMatteo BaucknehtMatteo BagnalastaStefania MazzagliaFederica ScalorbiGiovanni ArgiroffiMargarita KirienkoAlice LorenzoniGianluca AlibertiSara PuscedduCalareso GiuseppinaGaranzini Enrico MatteoEttore SeregniCarlo ChiesaPublished in: European journal of nuclear medicine and molecular imaging (2024)
Lu]Lu-DOTATATE offers an important prognostic value in the clinical decision-making process, especially for the future as alternative emitters or administration schedule may become available.